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ABSTRACT
Objective and Methods: In this phase 1b study, patients with stage 4 or 
unresectable stage 3 melanoma were treated with escalating doses of lenvatinib 
(once daily) and temozolomide (TMZ) (days 1–5) in 28-day cycles, to determine the 
maximum tolerated dose (MTD) of the combination. Dose Level (DL)1: lenvatinib 
20 mg, TMZ 100 mg/m2; DL2: lenvatinib 24 mg, TMZ 100 mg/m2; DL3: lenvatinib 
24 mg, TMZ 150 mg/m2. Adverse events (AEs) were recorded and tumor response 
assessed per RECIST 1.0.
Results: Dose-limiting toxicity occurred in 1 of 32 treated patients (DL1); MTD was 
not reached. The highest dose administered was lenvatinib 24 mg + TMZ 150 mg/m2.  
Most common treatment-related AEs included fatigue (56.3%), hypertension (53.1%), 
and proteinuria (46.9%). Overall objective response rate was 18.8% (6 patients), 
all partial response; (DL1, n = 1; DL3, n = 5). Stable disease (SD) ≥ 16 weeks was 
observed in 28.1% of patients (DL1 and DL2, n = 1 each; DL3, n = 7); 12.5% of 
patients had SD ≥ 23 weeks. Single and repeat-dose pharmacokinetics of lenvatinib 
were comparable across cycles and with concomitant TMZ administration.
Conclusion: Lenvatinib 24 mg/day + TMZ 150 mg/m2/day (days 1–5) demonstrated 
modest clinical activity, an acceptable safety profile, and was administered without 
worsening of either lenvatinib- or TMZ-related toxicities in this patient group.
INTRODUCTION
Melanoma has one of the fastest increasing incidence 
rates of any cancer [1, 2]. According to 2014 estimates, 
there were 76,100 new cases of, and 9710 deaths from, 
malignant melanoma in the United States. Approved 
treatments for metastatic melanoma have only recently 
demonstrated significant activity. These treatments include 
ipilimumab (human cytotoxic T-lymphocyte antigen 
4-blocking antibody), vemurafenib, dabrafenib (BRAF 
inhibitors), trametinib (MEK inhibitor), pembrolizumab 
(anti-programmed cell death 1 antibody), and nivolumab 
(an anti-PD1 receptor immune checkpoint inhibitor 
monoclonal antibody). Median overall survival with standard 
treatment is 7–15.9 months, and response rates range from 
10.2% to 53% [3–8]. Unfortunately, some patients do not 
respond, and most still develop recurrent disease.
Angiogenesis—the formation of new blood vessels—
is critical for tumor survival and progression [1, 2]. Genetic 
aberrations associated with angiogenic signaling pathways 
mediated by growth factors, including vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), 
and platelet-derived growth factor (PDGF), have been 
correlated with progression in metastatic melanoma [1, 2].
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Lenvatinib (E7080) is an orally active multikinase 
inhibitor of VEGF-receptor (VEGFR) 1–3, FGF-receptor 
(FGFR) 1–4, PDGF-receptor (PDGFR)-α, RET, and 
KIT proto-oncogenes [9]. In phase 1 studies, lenvatinib 
showed antitumor activity in solid-tumor patients at a 
maximum tolerated dose (MTD) of 25 mg/day [10, 11]. 
Temozolomide (TMZ) is an oral chemotherapeutic agent 
that shows evidence of response and similar efficacy 
to that of dacarbazine in melanoma, but it is also able to 
cross the blood–brain barrier, giving it a possible role in the 
treatment of melanoma patients with brain metastases [12]. 
TMZ is metabolized through nonenzymatic pH-dependent 
hydrolysis, and, therefore, has low potential for drug-drug 
interactions [13]. The combination of an alkylating agent 
and VEGF inhibitor has been previously proposed. In 
in vitro studies and in vivo xenograft models of melanoma, 
treatment with dacarbazine increased VEGF expression, 
providing a potential resistance mechanism to monotherapy 
[14, 15]. Preclinical data from a human melanoma xenograft 
study that evaluated a combination of lenvatinib and TMZ 
showed preliminary evidence of an additive efficacy (Eisai, 
Inc.; data on file).
We report here the phase 1b results of a phase 
1/1b study conducted to determine the MTD and 
pharmacokinetic profile of lenvatinib when given once 
daily in combination with TMZ as treatment for advanced 
melanoma. The safety and tolerability of the combination, 
tumor response, and potential biomarkers of efficacy of 
this combination were also evaluated.
RESULTS
Patients
A total of 32 patients with metastatic melanoma 
were enrolled across the 3 dose levels (DLs): DL1, 
n = 6; DL2, n = 4; and DL3, n = 22. The demographics 
and baseline characteristics for the overall study 
population are summarized in Table 1. The median age of 
patients was 57.5 years (range, 24–81). The majority of 
patients (65.6%) had an Eastern Cooperative Oncology 
Group (ECOG) performance score of 1, 62.5% were 
male, and 84% had received at least 1 prior chemotherapy 
regimen. Two patients, both in DL3, had previously 
received ipilimumab. The BRAFV600E tumor mutation was 
present in 7 (44%) of 16 evaluable patients and the NRAS 
tumor mutation was present in 6 (50%) of 12 evaluable 
patients.
Overall, 22 (68.8%) patients discontinued the 
study due to progressive disease (PD) or clinical 
deterioration (DL1, n = 4; DL2, n = 3; DL3, n = 15). 
Additionally, 5 patients withdrew consent (DL1, n = 1; 
DL3, n = 4), and 1 patient from each group discontinued 
due to adverse events (AEs) AEs (DL1) and physician’s 
decision (DL2). Three patients (9.4%) died either during 
study treatment or within 30 days after last dose (DL1, 
n = 2; DL3, n = 2).
Dose-limiting toxicities and maximum 
tolerated dose
One dose-limiting toxicity (DLT) (grade 3 
proteinuria) occurred in DL1. The MTD was not reached 
because no patients experienced a DLT at the highest 
combination dose (DL3). Investigators chose not to escalate 
the lenvatinib dosage beyond 24 mg/day (the established 
MTD for lenvatinib) or TMZ dose beyond 150 mg/m2 (the 
conventional dose level when combined with other drugs).
Safety
The safety population was comprised of all 
32 patients receiving at least 1 dose of study drug. Fatigue 
(56%), hypertension (53%), and proteinuria (47%) 
were the most commonly observed study-drug-related 
toxicities (Table 2). The most common National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (version 3.0) grade 3 study-drug-related toxicities 
in the overall study population were asthenia (13%), 
hypertension (9%), fatigue (6%), hyponatremia (6%), 
and proteinuria (6%), with most grade 3 toxicities seen in 
DL3 (Table 2). Only 1 grade 4 drug-related toxicity (DL3; 
myocardial infarction) occurred and was handled through 
dose adjustment. Overall, 31.3% of patients experienced 
only grade 1–2 toxicities. A total of 3 patients died during 
treatment or within 30 days of last dose. All 3 deaths 
appear to have been due to disease progression.
Pharmacokinetics
Overall, single-dose and repeat-dose PK parameters 
of lenvatinib were comparable across cycles and with 
concomitant TMZ administration (Supplementary Table 1). 
Lenvatinib area under the concentration-time curve 
extrapolation to time (AUC
(0–τ)
), area under the curve from 
time 0 extrapolated to infinite time (AUC
(0–inf)
), and peak 
plasma concentration (C
max
) were similar across the 3 cohorts 
following single- and repeat-dose administration. Similarly, 
the median time to peak concentration (t
max
), terminal 1/2 
life (t
1/2
), and clearance after oral administration (CL/F) 
estimates for lenvatinib were independent of the dose of 
lenvatinib or TMZ regimen. Following administration of 
treatment on cycle 2 day 1, the median t
max
 ranged between 
1 to 8 hours across the cohorts, and there was no apparent 
accumulation upon repeated administration of lenvatinib 
alone or in combination with TMZ (data not shown).
Tumor response and duration of treatment
Patients in DL1 received a median of 3.0 (range 1.5) 
cycles of both lenvatinib and TMZ, patients in DL2 received 
a median of 3.0 (2.0, 4.0) cycles of lenvatinib and 2.5 (2.0, 
4.0) cycles of TMZ, and patients in DL3 received a median 
of 4.0 (1.0, 7.0) cycles of lenvatinib and 3.5 (1.0, 7.0) cycles 
of TMZ. At the time of data cutoff, there were 4 partial 
responses (PRs) observed, with 3 patients still undergoing 
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treatment; in an updated analysis, 2 out of those 3 patients 
additionally achieved PR (personal communication, 
D.S. Hong). A best response of PR was, therefore, observed 
in 6/32 (18.8%) patients, with 1 PR (16.7%) in DL1 and 5 
PRs in DL3 (22.7%; Table 3). All 6 patients who achieved 
PR received lenvatinib for at least 3 treatment cycles (range, 
3–11 cycles). Stable disease (SD) ≥ 16 weeks was achieved 
by 9/32 (28.1%) patients; 1 patient each in DL1 and DL2, 
and 7 (31.8%) patients in DL3. Four (18.2%) patients in DL3 
had durable SD. Median progression-free survival (PFS) in 
DL3 was 5.4 months.
Figure 1 represents the maximum percentage change 
of target lesions from baseline in patients from DL3 stratified 
by BRAF and NRAS mutation status. Patients with wild 
type BRAF (BRAF
WT
) status (n = 7) seemed to have better 
overall response on treatment (P = 0.007). Two BRAFWT 
Table 1: Baseline Patient Characteristics
Category DL1
Lenvatinib 20 mg 
+ TMZ 100 mg/m2
(n = 6)
DL2
Lenvatinib 24 mg 
+ TMZ 100 mg/m2
(n = 4)
DL3
Lenvatinib 24 mg 
+ TMZ 150 mg/m2
(n = 22)
Combined
Total
(N = 32)
Age, years
 Mean (SD) 62.5 (9.71) 57.0 (8.08) 53.2 (13.97) 55.4 (12.94)
 Median 59.0 55.0 55.5 57.5
 Range (Min, Max) 55, 81 50, 68 24, 79 24, 81
Sex, n (%)
 Male 5 (83.3) 3 (75.0) 12 (54.5) 20 (62.5)
 Female 1 (16.7) 1 (25.0) 10 (45.5) 12 (37.5)
Race, n (%)
 Non-Hispanic White 4 (66.7) 4 (100) 19 (86.4) 27 (84.4)
 Hispanic 1 (16.7) 0 3 (13.6) 4 (12.5)
 African-American 1 (16.7) 0 0 1 (3.1)
ECOG scorea, n (%)
 0 3 (50.0) 2 (50.0) 6 (27.3) 11 (34.4)
 1 3 (50.0) 2 (50.0) 16 (72.7) 21 (65.6)
Previous anticancer treatments, n (%)
 Chemotherapy ≥ 1 5 (83.3) 3 (75.0) 19 (86.4) 27 (84.4)
 Radiotherapy 3 (50.0) 3 (75.0) 9 (40.9) 15 (46.9)
 Surgery 6 (100) 4 (100) 22 (100) 32 (100)
 Other anticancer 
treatment regimens 3 (50.0) 2 (50.0) 13 (59.1) 18 (56.3)
Previous chemotherapy regimens, n (%)
 0 1 (16.7) 1 (25.0) 3 (13.6) 5 (15.6)
 1 2 (33.3) 2 (50.0) 10 (45.5) 14 (43.8)
 2 2 (33.3) 0 4 (18.2) 6 (18.8)
 ≥3 1 (16.7) 1 (25.0) 5 (22.7) 7 (21.9)
Mutational status,a n (%)
 BRAF NA NA 7 (43.8) NA
 NRAS NA NA 6 (50.0) NA
a16 And 12 patient tumors were evaluable for BRAF and NRAS testing, respectively.
DL, dose level; ECOG, Eastern Cooperative Oncology Group; NA, not available; SD, standard deviation; 
TMZ, temozolomide.
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patients achieved PR; 5 had SD ≥ 16 weeks (2 had durable 
[ie, > = 23 weeks] SD). There was no significant correlation 
between NRAS mutation status and response (n = 5; 
P = 0.69).
DISCUSSION
The MTD was not reached in this phase 1b 
combination treatment portion of the study because 
no patients experienced a DLT at the maximum 
administered dose of the combination treatment (DL3 
once daily); however, the investigators felt it would have 
been inappropriate to further escalate either one of the 
drugs. The single DLT reported in this population was 
grade 3 proteinuria in DL1. The highest dose for further 
clinical evaluation of this combination was defined as 
lenvatinib 24 mg/day, days 1–28, plus TMZ 150 mg/m2, 
days 1–5.
Table 2: Adverse Events Occurring in ≥ 20% of Overall Patients and CTC Grade 3 Drug-related Adverse Events 
Occurring in at Least 2 Patients
DL1
Lenvatinib 20 mg 
+ TMZ 100 mg/m2
(n = 6)
n (%)
DL2
Lenvatinib 24 mg 
+ TMZ 100 mg/m2
(n = 4)
n (%)
DL3
Lenvatinib 24 mg 
+ TMZ 150 mg/m2
(n = 22)
n (%)
Combined
Total
(N = 32)
n (%)
Patients with treatment-
related all-grade AEs 6 (100) 4 (100) 20 (90.9) 30 (93.8)
≥20% All-grade drug-
related TEAEs
 Fatigue 4 (66.7) 3 (75.0) 11 (50.0) 18 (56.3)
 Hypertension 5 (83.3) 1 (25.0) 11 (50.0) 17 (53.1)
 Proteinuria 3 (50.0) 1 (25.0) 11 (50.0) 15 (46.9)
 Hypothyroidism 3 (50.0) 1 (25.0) 10 (45.5) 14 (43.8)
 Anorexia 3 (50.0) 2 (50.0) 9 (40.9) 14 (43.8)
 Nausea 2 (33.3) 1 (25.0) 9 (40.9) 12 (37.5)
 Vomiting 2 (33.3) 0 10 (45.5) 12 (37.5)
 Diarrhea 2 (33.3) 1 (25.0) 8 (36.4) 11 (34.4)
 Thrombocytopenia 0 0 8 (36.4) 8 (25.0)
 Asthenia 1 (16.7) 1 (25.0) 6 (27.3) 8 (25.0)
  Blood thyroid 
stimulating hormone 
increased
0 1 (25.0) 6 (27.3) 7 (21.9)
Patients with CTC 
grade 3 drug-related 
TEAEsa
2 (33.3) 2 (50.0) 9 (40.9) 13 (40.6)
CTC grade 3 drug-related 
TEAEs
 Asthenia 0 1 (25.0) 3 (13.6) 4 (12.5)
 Hypertension 1 (16.7) 0 2 (9.1) 3 (9.4)
 Fatigue 0 0 2 (9.1) 2 (6.3)
 Hyponatremia 0 0 2 (9.1) 2 (6.3)
 Proteinuria 1 (16.7) 1 (25.0) 0 2 (6.3)
aGrade 4 drug-related TEAE occurred in 1 patient (myocardial infarction).
AEs, adverse events; CTC, common terminology criteria; DL, dose level; TEAE, treatment-emergent adverse event; 
TMZ, temozolomide.
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Table 3: Best Overall Tumor Responses
Best Overall Tumor 
Responsea
DL1
Lenvatinib 20 mg + 
TMZ 100 mg/m2
(n = 6)
n (%)
DL2
Lenvatinib 24 mg + 
TMZ 100 mg/m2
(n = 4)
n (%)
DL3
Lenvatinib 24 mg + 
TMZ 150 mg/m2
(n = 22)
n (%)
Combined
Total
(N = 32)
n (%)
Complete response 0 0 0 0
Partial response 1 (16.7) 0 5 (22.7) 6 (18.8)
Stable disease 4 (66.7) 2 (50.0) 9 (40.9) 15 (46.9)
≥16 Weeks 1 (16.7) 1 (16.7) 7 (31.8) 9 (28.1)
 ≥23 Weeksb 0 0 4 (18.2) 4 (12.5)
Progressive disease 1 (16.7) 1 (25.0) 5 (22.7) 7 (21.9)
Unknownc 0 1 (25.0) 3 (13.6) 4 (12.5)
DL, dose level; SD, stable disease; TMZ, temozolomide.
aResponses evaluated based on RECIST 1.0 (Response Evaluation Criteria In Solid Tumors version 1.0). Responses for 
3 patients were updated after the primary analysis because they were still on treatment at data cut-off: 2 Patients achieved 
partial responses, 1 patient achieved stable disease ≥23 weeks (personal communication, D.S. Hong).
bDurable SD is defined as SD lasting ≥23 weeks.
cUnknown – not assessable or insufficient data.
*3 Patients with PD and 2 patients with clinical deterioration were included in the waterfall arbitrarily at a 21% increase. Responses for 
3 patients were updated after the primary analysis, since they were still on treatment at data cut-off: 2 Patients achieved partial responses, 
1 patient achieved stable disease ≥23 weeks (personal communication, D.S. Hong).
Figure 1: Patients with advanced/metastatic melanoma treated with the combination of lenvatinib and temozolomide. 
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The combination therapy of lenvatinib and TMZ 
generally had an acceptable toxicity profile in patients 
with advanced melanoma, and it was given at the 
highest level of DL3 without apparent worsening of 
either lenvatinib- or TMZ-related toxicities. The most 
common treatment-emergent adverse events (TEAEs) 
considered related to study drug by investigators included 
fatigue, hypertension, proteinuria, hypothyroidism, and 
anorexia. The incidences of several TEAEs, including 
hypothyroidism and thrombocytopenia (46.9% each), in this 
combination study were higher compared with those in a 
study of lenvatinib alone (15.6% and 13.0%, respectively). 
This difference may be due to the combination treatment 
(lenvatinib plus TMZ) or due to TMZ alone.
TMZ has a safety and efficacy profile similar to the 
current standard of care, dacarbazine. A benefit of adding 
TMZ to metastatic melanoma therapy may be its ability 
to cross the blood-brain barrier [12]. Single-agent TMZ 
has been associated with response rates of 0% to 29% in 
patients with metastatic melanoma [12]. In combination 
with interferon alpha, response rates of 13% to 23% have 
been reported [12]. An uncontrolled phase 2 study of TMZ 
in combination with sorafenib also demonstrated activity 
in TMZ-naïve patients with melanoma, including patients 
with brain metastases [16].
In the present study of TMZ and lenvatinib as 
a combination therapy, we observed a best overall 
response of PR in 18.8%, and SD ≥ 16 weeks in 28.1% 
of the overall population. In addition, 4 patients in DL3 
experienced durable SD ≥ 23 weeks. Best overall response 
was not evaluable or censored in 4 patients. However, the 
response rates observed with TMZ and lenvatinib in the 
present study are lower than a 61% objective response rate 
(44 of 72 patients) observed in patients with melanoma 
receiving a combination of ipilimumab and nivolumab 
[17], and lower than a 31.7% objective response rate (38 or 
120 patients) observed in a phase 3 trial of nivolumab in 
patients with metastatic melanoma whose disease had 
progressed after previous treatment with ipilimumab, or 
treatment with ipilimumab and a BRAF inhibitor if their 
tumors harbored a BRAF V600E mutation [18].
Overall, in our analysis of pharmacokinetic 
parameters, we found that the single-dose and repeat-dose 
pharmacokinetics of lenvatinib were comparable across 
cycles and with concomitant TMZ administration. Estimates 
of t
1/2,
 t
max
, and CL/F for lenvatinib were independent of 
the dose of lenvatinib or TMZ. The pharmacokinetics of 
lenvatinib 24 mg in combination with TMZ was comparable 
to that seen when lenvatinib was given as a monotherapy 
and there was no evidence for accumulation upon repeated 
administration of lenvatinib alone or in combination 
with TMZ.
Angiopoietins are ligands of the endothelial cell 
receptor soluble Tie-2 (sTie-2) and have crucial roles in 
tumor angiogenic switches [1]. In malignant melanoma, 
soluble angiopoietin-2 (sAng-2) levels are elevated and 
may function as part of an autocrine Ang-2/Tie2 growth 
loop. Circulating levels of sAng-2 have been correlated 
with tumor load, disease stage, and overall survival [19]. 
The relationship observed between maximum tumor 
shrinkage (MTS) and change in levels of Ang-2 in the 
current study suggests that this angiogenic pathway may 
be associated with the activity of lenvatinib.
The tumor gene mutation analyses performed in this 
study indicated that BRAFWT  status appeared to correlate 
with better response to this combination treatment. No 
clear correlation between response and NRAS mutation 
status could be made. Due to the fairly small sample size 
and exploratory nature of these biomarker analyses, these 
findings should be further explored in larger ongoing 
studies of lenvatinib.
In conclusion, the combination of lenvatinib 
with TMZ had an acceptable toxicity profile and can be 
administered without increase in toxicity of either agent. 
This combination therapy demonstrated modest clinical 
activity in a population of patients with unresectable 
stage 3 or stage 4 melanoma. These results will be further 
confirmed in ongoing phase 2 studies of lenvatinib in 
advanced melanoma. Additional studies are also underway 
to further explore the potential role of lenvatinib in 
treatment of advanced or metastatic melanoma.
MATERIALS AND METHODS
Patients
This was a phase 1/1b, open-label study 
(NCT00121680) conducted at the University of Texas 
MD Anderson Cancer Center and the Mary Crowley 
Cancer Research Center. The main inclusion criteria 
were: patients aged ≥ 18 years with a histological and/or 
cytological confirmed diagnosis of advanced or metastatic 
melanoma untreatable by standard therapies; melanoma 
lesions amenable to biopsy; adequate renal, hepatic, and 
hematologic parameters; and an ECOG performance status 
of 0 or 1. Patients who were intolerant of TMZ or any 
of its excipients, pregnant, required full-dose aspirin or 
chronic nonsteroidal anti-inflammatory drugs, or were 
untreated for or had unstable central nervous system 
metastases were excluded.
The study was conducted in accordance with World 
Medical Association Declaration of Helsinki and the 
International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use guidelines. Prior to study participation, all 
participants provided written informed consent. The 
Mary Crowley Cancer Research Center and University of 
Texas MD Anderson Cancer Center Institutional Review 
Boards approved the study. A separate publication details 
results of the monotherapy portion of the phase 1 study 
of lenvatinib in solid tumors (including a melanoma 
population).
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Study design
This phase 1b study utilized a standard “3+3” dose-
escalation scheme to evaluate the MTD of lenvatinib in 
combination with TMZ. Patients were treated in sequential 
cohorts of escalating dosing of lenvatinib (continuous 
once daily) and TMZ (days 1–5) in a 28-day treatment 
cycle. The initial doses were lenvatinib 20 mg once daily 
with TMZ 100 mg/m2/day for days 1–5 (DL1). Subsequent 
doses were lenvatinib 24 mg with TMZ 100 mg/m2 (DL2) 
and lenvatinib 24 mg with TMZ 150 mg/m2 (DL3).
DLTs were assessed once the first 3 patients completed 
1 treatment cycle. Any of the following events was defined 
as a DLT: any hematologic toxicity of grade 3 or higher; 
any nonhematologic toxicity of grade 3 or higher, with the 
exception of grade 3 hypertension that could be controlled 
(via intensification of single agent antihypertensive 
treatment or by adding a second antihypertensive); and any 
failure to administer ≥ 75% of the study drugs during cycle 
1 due to treatment-related toxicities. The MTD was defined 
as the highest dose tolerated by a minimum of 5 out of the 
first 6 treated patients.
Procedures
Blood samples were collected on cycle 1, day 1 
(C1D1) immediately prior to the first dose of lenvatinib 
and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, and 24 hours 
following administration on C1D1 and day 1 cycle 2. 
Additional samples were collected prior to lenvatinib 
administration on days 8, 15, and 22 of cycle 1, as well 
as on day 1 of cycles 3 and 4. T
max
, C
max
, C
trough
, AUC
0-t
, 
CL (total body clearance from plasma), Vss (volume of 
distribution at steady rate), and t
1/2
 were evaluated.
Pharmacodynamic assessments of lenvatinib 
were conducted based on serum samples collected prior 
to study drug administration and at 2 hours following 
administration on C1D1, as well as prior to administration 
on days 8, 15, and 22 of cycle 1. Serum samples were 
tested for angiogenesis-related markers (MDS Pharma/
Clearstone Central Lab) and apoptosis-related (Pathway 
Diagnostics/Quest) markers. These angiogenesis-
related markers were PDGF-homodimer BB, sTie-2 
(receptor expressed by endothelial cells), angiopoietin-1 
(Tie-2 ligand), soluble E-selectin (mediates leukocyte 
and tumor cell rolling), and soluble c-kit. The apoptosis-
related markers assessed were cytochrome C (a measure 
of intrinsic apoptotic pathway activation) and M30 
neoantigen (caspase-cleaved cytokeratin-18, also a 
terminal apoptotic product for epithelial-derived tumors). 
sTie-2, angiopoietin-1, PDGF-BB, soluble e-selectin, 
soluble c-kit, cytochrome C, and M30 were measured 
by enzyme-linked immunosorbent assay. PDGF-BB was 
assayed by Luminex Technology using Growth Factor 
Buffer Reagent and a Human Custom Multiplex Antibody 
Bead Kit from BioSource Invitrogen (Frederick, MD). 
Pretreatment (baseline) and posttreatment changes in 
levels of additional serum cytokine and angiogenic factors 
(CAF), including Ang-2, sVEGFR1-3, sTie-2, PDGF-AB, 
PDGF-BB, VEGFA, FGF4, VEGFD, hepatocyte growth 
factor, FMS-related tyrosine kinase 3 ligand (FLT3LG), 
and placental growth factor were evaluated. CAFs were 
measured in house by Eisai.
Safety assessments were performed in each 
cycle by physical examination, weekly blood pressure 
monitoring, periodic measurement of vital signs and 
electrocardiograms, ECOG performance status evaluation, 
and regular monitoring of hematology, blood chemistry, 
and urine values. All AEs and serious AEs were recorded.
Tumor assessments were conducted at baseline and 
approximately every 8 weeks during treatment. Responses 
were confirmed after ≥ 30 days using Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.0 [20]. 
Tumor responses were assessed by computed tomography, 
magnetic resonance imaging, or, in the case of skin lesions, 
photography and clinical examination. Tumor responses 
were classified as either complete response (CR), PR, SD, 
or progressive disease (PD). SD was further stratified as 
SD maintained for ≥ 7weeks and ≥ 16 weeks, and durable 
SD was defined as SD maintained for ≥ 23 weeks. 
Tumor mutation analysis
Paraffin-embedded tumor samples were macrodis-
sected using a dissecting microscope and analyzed for 
BRAF and NRAS mutations at the Clinical Laboratory 
Improvement Amendments-certified Molecular Diagnostics 
Laboratory at MD Anderson using standard operating 
procedures.
Statistical analysis
Baseline and demographic variables including age, 
gender, race, height, weight, and ECOG performance 
score were summarized using descriptive statistics. 
Plasma concentrations of lenvatinib were analyzed and 
summarized using descriptive statistics for the following 
pharmacokinetic parameters: CL/F, AUC, C
max
, C
trough
, t
max
, 
and t
1/2
. Pearson and Spearman correlation coefficients 
were calculated between pharmacokinetic parameters 
and serum biomarkers at different time points compared 
with baseline to examine the correlation between drug 
exposure and biomarkers. Univariate and multivariate Cox 
proportional hazards models and log-rank tests were used 
to examine the relationship between PFS and baseline 
(and change from baseline) concentrations in angiogenesis 
and apoptosis biomarkers. Cumulative chi-square test 
was used to examine the correlation between mutation/
serum biomarkers and best overall response. Pearson and 
Spearman correlation coefficients were also calculated 
between percent MTS (defined as percent change in sum 
of longest diameter from baseline to nadir using RECIST 
criteria) and serum biomarkers at different time points 
compared with baseline.
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